Mark Daly
Chief Technology Officer Digital Diagnostics
I helped lead my startup through the challenges of finding a product-market fit, integrating into a global company with a different culture, and scaling our solution to launch globally. Watching software my co-founders and I whiteboarded a decade earlier be deployed to coordinate planning and response to the global pandemic was a highly rewarding and educational experience. Trained in computer engineering with decades of practical experience at all levels of information technology, from help-desk to on-call sysadmin to engineering manager, I have worn many hats in my career before I discovered my passion is product development. I am looking for the next challenge where I can leverage this experience to help launch a great technology solution for an organization with a positive culture and mission to help people.
Seminars
This dynamic fishbowl debate brings engineers, clinicians, and regulatory leaders into a rotating inner‑circle conversation, creating a rare, real‑time exchange between those designing AI systems, those deploying them, and those overseeing their safety. With audience members stepping into the discussion throughout, the session becomes a living model of the very human‑machine interaction it examines.
- Discuss how assistive, decision‑support, and autonomous AI shift risk, validation, and oversight, enabling attendees to match autonomy levels to the appropriate regulatory and safety strategy
- Examine where AI improves consistency and where it introduces over‑reliance or hidden errors, giving participants clearer judgment on when human review adds safety value
- Explore how claims, labelling, and clinical context constrain autonomy, helping attendees align design decisions with regulatory positioning
- Break down models for “human in the loop,” “on the loop,” and supervisory control guiding teams to design workflows, interfaces, and monitoring that meet regulator and clinician expectations
- The gap between algorithm performance and deployable medical products
- Regulatory, usability, and reimbursement barriers that stall innovation
- Lessons from companies that successfully crossed the “last mile”
- What investors, regulators, and customers now expect from software-driven devices
